IMPORTANT INVESTOR ALERT: Marcus & Boxerman Announces an Ongoing Investigation of BofI Holding, Inc. and Encourages Investors to Contact the Firm

CHICAGO--(BUSINESS WIRE)-- Marcus & Boxerman announces that it is investigating claims of potential misrepresentations by BofI Holding, Inc. (“BofI” or the “Company”) (Nasdaq: BOFI). The investigation will focus on whether the Company and its officers violated securities laws by issuing misleading statements and/or failing to disclose material information to investors.

To participate in this class action lawsuit, please contact Michael Boxerman, Esquire, of Marcus & Boxerman, at 312-216-2730, or via email at [email protected].

The investigation will focus on whether the Company made false and/or misleading statements and/or failed to disclose that: (1) BofI’s internal controls were frequently disregarded; (2) BofI’s borrowers included foreign nationals who should have been off-limits under federal anti-money-laundering laws; (3) many BofI accounts lacked required tax identification numbers; and (4) BofI fired an internal auditor who raised these issues to management and to federal regulators.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151125005903/en/

Marcus & Boxerman
Michael Boxerman, Esq., 312-216-2730
[email protected]
Facsimile: 312-216-2720

Source: Marcus & Boxerman

You May Also Be Interested In

• PRUVN Reveals Human Clinical Trial Results of Max International's RiboCeine™ Supplementation's Impact on Serum Glutathione Levels
• Interactive Kiosk Market Anticipated to Cross $58.92 billion By 2031, at 8.7% CAGR | Advanced Kiosks, Advantech, NCR Corp, Glory Ltd
• RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatment